Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.10.5687

PKCδ-dependent Activation of the Ubiquitin Proteasome System is Responsible for High Glucose-induced Human Breast Cancer MCF-7 Cell Proliferation, Migration and Invasion  

Zhu, Shan (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Yao, Feng (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Li, Wen-Huan (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Wan, Jin-Nan (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Zhang, Yi-Min (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Tang, Zhao (Department of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences)
Khan, Shahzad (Department of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences)
Wang, Chang-Hua (Department of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences)
Sun, Sheng-Rong (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.10, 2013 , pp. 5687-5692 More about this Journal
Abstract
Type 2 diabetes mellitus (T2DM) has contributed to advanced breast cancer development over the past decades. However, the mechanism underlying this contribution is poorly understood. In this study, we determined that high glucose enhanced proteasome activity was accompanied by enhanced proliferation, migration and invasion, as well as suppressed apoptosis, in human breast cancer MCF-7 cells. Proteasome inhibitor bortezomib (BZM) pretreatment mitigated high glucose-induced MCF-7 cell growth and invasion. Furthermore, high glucose increased protein kinase C delta ($PKC{\delta}$)-phosphorylation. Administration of the specific $PKC{\delta}$ inhibitor rottlerin attenuated high glucose-stimulated cancer cell growth and invasion. In addition, $PKC{\delta}$ inhibition by both rottlerin and $PKC{\delta}$ shRNA significantly suppressed high glucose-induced proteasome activity. Our results suggest that $PKC{\delta}$-dependent ubiquitin proteasome system activation plays an important role in high glucose-induced breast cancer cell growth and metastasis.
Keywords
High glucose; ubiquitin proteasome system; protein kinase C ${\delta}$; breast cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sasaki S, Inoguchi T (2012). The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J, 36, 255-61.   DOI   ScienceOn
2 Warburg, O (1956). On the origin of cancer cells. Science, 123, 309-14.   DOI
3 Sato K, Rajendra E, Ohta T (2008). The UPS: a promising target for breast cancer treatment. BMC Biochem, 9, S2.   DOI   ScienceOn
4 Smith HJ, Wyke SM, Tisdale MJ (2004). Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes. Br J Cancer, 90, 1850-7.
5 Srivastava AK (2002). High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med, 9, 85-9.
6 Wing SS (2008). The UPS in diabetes and obesity. BMC Biochem, 9, S6.   DOI   ScienceOn
7 Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005). Diabetes mellitus and breast cancer. Lancet Oncol, 6, 103-11.   DOI   ScienceOn
8 Wu WK, Cho CH, Lee CW, et al (2010). Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett, 293, 15-22.   DOI   ScienceOn
9 Wu WS (2006). The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev, 25, 695-705.
10 Ciechanover A, Orian A, Schwartz AL (2000). Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays, 22, 442-51.   DOI
11 Ciechanover A, Schwartz AL (1994). The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J, 8, 182-91.
12 Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004). Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol, 159, 1160-7.   DOI   ScienceOn
13 Driscoll JJ, Woodle ES (2012). Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol, 49, 277-83.   DOI   ScienceOn
14 Cvek B, Dvorak Z (2011). The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm Des, 17, 1483-99.   DOI   ScienceOn
15 Dang CV, Semenza GL (1999). Oncogenic alterations of metabolism. Trends Biochem Sci, 24, 68-72.   DOI   ScienceOn
16 Dees EC, Orlowski RZ (2006). Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol, 2, 121-35.   DOI   ScienceOn
17 Goldberg AL (2003). Protein degradation and protection against misfolded or damaged proteins. Nature, 426, 895-9.   DOI   ScienceOn
18 Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ (2007). Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog, 46, 381-90.   DOI   ScienceOn
19 Bence NF, Sampat RM, Kopito RR (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-5.   DOI   ScienceOn
20 Bugliani M, Liechti R, Cheon H, et al (2013). Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitin-proteasome system in pancreatic beta cell dysfunction. Mol Cell Endocrinol, 367, 1-10.   DOI   ScienceOn
21 Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE (2011). Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov, 10, 29-46.   DOI   ScienceOn
22 Kiley SC, Clark KJ, Duddy SK, Welch DR, Jaken S (1999). Increased protein kinase C delta in mammary tumor cells: relationship to transformtion and metastatic progression. Oncogene, 18, 6748-57.   DOI
23 Hauptmann S, Grunewald V, Molls D, et al (2005). Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. Anticancer Res, 25, 3431-6.
24 Hochstrasser M (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol, 7, 215-23.   DOI   ScienceOn
25 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
26 Kirk-Ballard H, Wang ZQ, Acharya P, et al (2013). An extract of Artemisia dracunculus L. inhibits ubiquitin-proteasome activity and preserves skeletal muscle mass in a murine model of diabetes. PLoS One, 8, e57112.   DOI   ScienceOn
27 Kroemer G, Pouyssegur J (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 13, 472-82.   DOI   ScienceOn
28 Landis-Piwowar KR, Milacic V, Chen D, et al (2006). The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat, 9, 263-73.   DOI   ScienceOn
29 Larsson SC, Mantzoros CS, Wolk A (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 121, 856-62.   DOI   ScienceOn
30 Liao S, Li J, Wang L, et al (2010). Type 2 diabetes mellitus and characteristics of breast cancer in China. Asian Pac J Cancer Prev, 11, 933-7.
31 Liao S, Li J, Wei W, et al (2011). Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev, 12, 1061-5.
32 Masur K, Vetter C, Hinz A, et al (2011). Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer, 104, 345-52.   DOI   ScienceOn
33 Marfella R, Di Filippo C, D'Amico M, Paolisso G (2007). Diabetes, ubiquitin proteasome system and atherosclerotic plaque rupture. Circ Res, 100, e84-5.   DOI   ScienceOn
34 Marfella R, Di Filippo C, Portoghese M, et al (2009). The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol, 18, 332-45.   DOI   ScienceOn
35 Micel LN, Tentler JJ, Smith PG, Eckhardt GS (2013). Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol, 31, 1231-8.   DOI   ScienceOn
36 Orlowski RZ, Dees EC (2003). The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res, 5, 1-7.   DOI   ScienceOn
37 Rubinsztein DC (2006). The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443, 780-6.   DOI   ScienceOn
38 Gillies RJ, Gatenby RA (2007). Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr, 39, 251-7.   DOI
39 Liu Z, Miers WR, Wei L, Barrett EJ (2000). The ubiquitin-proteasome proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes. Biochem Biophys Res Commun, 276, 1255-60.   DOI   ScienceOn
40 Naujokat C, Berges C, Hoh A, et al (2007). Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology, 120, 120-32.